Avacincaptad pegol 2 mg for Macular Degeneration
Phase-Based Progress Estimates
Effectiveness
Safety
Retina Foundation of the Southwest, Dallas, TX
Macular Degeneration+2 More
Avacincaptad pegol 2 mg intravitreal injection - DrugEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
Patients who completed Study ISEE2008 (GATHER2) and consent to participate will be administered monthly avacincaptad pegol 2 mg.
Eligible Conditions
- Macular Degeneration
- Geographic Atrophy
Treatment Effectiveness
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: Month 18
Month 18
Adverse Events
Trial Safety
Trial Design
1 Treatment Group
Avacincaptad pegol 2 mg
1 of 1
Experimental Treatment
400 Total Participants · 1 Treatment Group
Primary Treatment: Avacincaptad pegol 2 mg · No Placebo Group · Phase 3
Avacincaptad pegol 2 mg
Drug
Experimental Group · 1 Intervention: Avacincaptad pegol 2 mg intravitreal injection · Intervention Types: DrugTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: month 18
Closest Location: Retina Foundation of the Southwest · Dallas, TX
2014First Recorded Clinical Trial
16 TrialsResearching Macular Degeneration
23 CompletedClinical Trials
Eligibility Criteria
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You are a male or female patient aged 50 years or greater diagnosed with GA inside and/or outside of the fovea who completed Study ISEE2008 (GATHER2) through the Month 24 visit on study treatment.
You must provide new written informed consent for this OLE trial prior to participation.
You must be able to return for all trial visits for the duration of the 18-month trial.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments